Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07296263 · ClinicalTrials.gov registry record · NA
Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems
A NA study of Intra-axial Tumors and Extra-axial Tumors, sponsored by Hyperfine.
- Recruiting
- Registry status
- NA
- Development phase
- 85
- Enrollment target
- 1
- Study location
NCT07296263 is a NA study of Intra-axial Tumors and Extra-axial Tumors that is actively recruiting participants, run by Hyperfine. The registered enrollment target is 85 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07296263, a NA study of Intra-axial Tumors and Extra-axial Tumors, is actively recruiting participants, sponsored by Hyperfine.
- RECRUITING
- Registry status
- NA
- Development phase
- 85 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, multi-center, interventional study designed to evaluate the visualization benefits of FDA approved gadolinium-based contrast agents (GBCAs) in portable magnetic resonance imaging (pMRI) of the brain. The study will enroll adult patients with known or suspected brain lesions involving blood-brain barrier disruption. Each participant will undergo a pre-contrast pMRI scan, receive an intravenous GBCA injection, and then complete a post-contrast pMRI scan using the Swoop® Portable MR Imaging® System. Lesion visualization will be assessed by independent neuroradiologists using standardized scoring criteria. The study will be conducted across a minimum of three sites to ensure diversity in patient population, imaging environments, and GBCA types.
Conditions Studied
Interventions
- OTHER Evaluation of Gadolinium Based Contrast Agents (GBCA) for Portable MR Imaging Systems
Study Locations (1)
Texas
- Texas Neurology - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2025-12-30 |
| Est. Completion | 2026-06-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07296263
The ClinicalTrials.gov registry entry for NCT07296263 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hyperfine, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Intra-axial Tumors appearing as the primary indexed condition, and to 1 intervention - of which Evaluation of Gadolinium Based Contrast Agents (GBCA) for Portable MR Imaging Systems is the first listed.
NCT07296263 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07296263 about?
NCT07296263 is a clinical study titled "Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems". This is a prospective, multi-center, interventional study designed to evaluate the visualization benefits of FDA approved gadolinium-based contrast agents (GBCAs) in portable magnetic resonance imaging (pMRI) of the brain. The study will enroll adult patients with known or suspected brain lesions in...
What is the current status of trial NCT07296263?
This trial is currently recruiting. It is a NA study. The enrollment target is 85 participants. The study started on 2025-12-30. Estimated completion is 2026-06-01.
What conditions does trial NCT07296263 study?
This clinical trial studies the following conditions: Intra-axial Tumors, Extra-axial Tumors, Infection/Inflammatory Lesions.
What interventions are being tested in trial NCT07296263?
The interventions under investigation include: Evaluation of Gadolinium Based Contrast Agents (GBCA) for Portable MR Imaging Systems (OTHER).
Who is sponsoring clinical trial NCT07296263?
This trial is sponsored by Hyperfine, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07296263 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.